[Carminomycin in combination with some cytostatics. 1. Efficacy in leukemia L1210].
Additive an synergistic therapeutic effects are demonstrable in the murine L 1210 model following combined application of CRM with CTX. Cytostasane, 5-FU, DTIC and CCNU, while combinations of CRM with L-PAM, BLM, DBD, CLB or MTX gave no such effects.
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002360:Carubicin / Q000627:therapeutic use*; D003630:Daunorubicin / Q000031:analogs & derivatives*; D004353:Drug Evaluation, Preclinical; D004359:Drug Therapy, Combination; D007939:Leukemia L1210 / Q000188:drug therapy*; D007958:Leukocyte Count; D051379:Mice
D000970:Antineoplastic Agents; D002360:Carubicin; D003630:Daunorubicin
Carminomycin in Kombination mit eingeführten Zytostatika. 1. Wirksamkeit an der Leukämie L 1210.